Concord Biotech (NSE:CONCORDBIO, BOM:543960) has acquired a 75% in US-based Stellon Biotech for $15,000, making it a subsidiary, to expand its business operations in the US, according to a Wednesday filing to the Indian stock exchanges.
The company subscribed 15 million equity shares of Stellon Biotech at $0.0001 per share.
Stellon is currently in its pre-revenue phase and was formed to support the marketing and commercialization of products developed by Concord Biotech.
The equity shares against the current investment will be allotted within 90 days.
The company's shares were down over 1% in recent trade.